[BATBA CAREER FORUM]
Could you imagine extending your research after graduate school? Let's see what the early R&D career looks like in the industry!
Scientific track in early R&D
The aim of research and development (R&D) is to improve the current technologies offered by an organisation or to develop innovations that strengthen the organisation’s position in the marketplace. The sector includes many companies that are dedicated research and development businesses that focus on particular fields or areas of work. For Biotech, the early end of R&D is close to what we perform daily in academia and the positions are pretty open to candidates thinking about working in industry.
This April, BATBA CAREER FORUM will present the special topic of Career Development in Early R&D. We invite three excellent speakers: Linya Wang, who is currently working as a bench scientist, and Jeremy Ku and Che-Yu Jerry Lee, whose daily jobs are mainly focusing on bioinformatics, to share their experience in the industry.
Dr. Ku shares a passion for abstraction in mathematics and mysteries in biological science. Upon completion of his M.S. and Ph.D. degrees in Electrical and Computer Engineering from Cornell University, NY, he has undertaken a career journey in which he collaborates closely with experimental scientists and leverages his analytical skills to address biomedical challenges.
Dr. Ku has extensive R&D experience in both academia and industry. His work has contributed to the development of commercial assays for early detection and personalized treatment of cancer. Currently Dr. Ku is working at Roche Diagnostics to build a suite of innovative solutions in women's health that will enable physicians to provide the right treatment at the right time with confidence. Dr. Ku is passionately dedicated to power precision medicine with cutting-edge data analytics to revolutionize public healthcare.
Che-Yu Jerry Lee:
Dr. Lee is currently working at Guardant Health as a senior bioinformatics scientist. Guardant Health received FDA approval for their liquid biopsy test for tumor profiling in 2020. They are also developing blood tests for early detection and recurrence monitoring in cancer survivors. Prior to entering the bioindustry field, Dr. Lee received his Ph.D. in Computational Biology at University of Southern California. He is focusing on mutation detection with NGS data and developing algorithms to reduce the noise and establish quality control standards.
Dr. Wang is a microbiologist and cell biologist. She is now working as a Staff Scientist at Twist Bioscience, which focuses on GPCR assay development and therapeutic antibody drug discovery that can be applied to immunotherapy, cell therapy, and target therapy. Prior to entering the industrial field, she received her Ph.D. in Microbiology at National Taiwan University College of Medicine, and worked in Institute of Molecular Biology at Academia Sinica, Taiwan. She then finished her postdoctoral training in Molecular Microbiology and Immunology at University of Southern California, USA.. She has also been involved in National Taiwan University Alumni Association as the President of Young Professional Group, Taiwanese Junior Chamber of Commerce as the Board of Director, Southern California Taiwanese Biotechnology Association as the President, and Bay Area Taiwanese Biotechnology Association as the President.